CASI Pharmaceuticals (CASIF) Other Non-Current Liabilities (2021 - 2025)

CASI Pharmaceuticals (CASIF) has 5 years of Other Non-Current Liabilities data on file, last reported at $13.3 million in Q4 2025.

• Quarterly Other Non-Current Liabilities fell 13.72% year-over-year to $13.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.3 million (down 13.72% YoY) and the FY2025 annual result came in at $13.3 million, down 13.72% from the prior year.
• Other Non-Current Liabilities declined to $13.3 million in Q4 2025, from $13.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $15.5 billion in Q4 2023 to a low of $12.3 million in Q4 2022.
• A 5-year average of $5.2 billion and a median of $15.4 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 125800.63% — and 2025, when it slumped 99.9%.
• Tracing CASIF's Other Non-Current Liabilities over 5 years: stood at $14.3 million in 2021, then declined by 14.16% to $12.3 million in 2022, then surged by 125800.63% to $15.5 billion in 2023, then tumbled by 99.9% to $15.4 million in 2024, then slipped by 13.72% to $13.3 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $13.3 million (Q4 2025), $13.6 million (Q3 2025), and $13.8 million (Q2 2025), per Business Quant data.